No CrossRef data available.
Article contents
Introduction to Neurotherapeutics and Neuropsychopharmacology
Published online by Cambridge University Press: 15 February 2006
Abstract
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Review Article
- Information
- Progress in Neurotherapeutics and Neuropsychopharmacology , Volume 1 , Issue 1 , January 2006 , pp. 1 - 12
- Copyright
- © 2006 Cambridge University Press
References
Cummings, J.L. (2000). Cholinesterase inhibitors: a new class of psychotropic compounds. American Journal of Psychiatry, 157, 4–15.Google Scholar
Cummings, J.L. (2003). Toward a molecular neuropsychiatry of neurodegenerative disease. Annals of Neurology, 54, 147–154.Google Scholar
Cummings, J.L. (2004). Alzheimer's disease. New England Journal of Medicine, 351, 56–67.Google Scholar
Emre, M., Aarsland, D., Albanese, A., et al. (2004). Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine, 351, 2509–2518.Google Scholar
Jacobs, B.L., Praag, H.V., Gage, F.H., et al. (2000). Adult brian neurogenesis and psychiatry: a novel theory of depression. Molecular Psychiatry, 5, 262–269.Google Scholar
Klunk, W.E., Engler, H., Nordberg, A., et al. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Annals of Neurology, 55, 306–319.Google Scholar
Lee, C.J., Lee, L.H., Lu, C., et al. (2003). Development and Evaluation of Drugs (2nd edn.). CRC Press, Boca Raton, Florida.
Ng, R. (2004). Drugs from Discovery to Approval. Wiley-Liss, Hoboken, New Jersey.